ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">ROCKVILLE, Md.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">Aug. 25, 2026</span> /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RGNX">RGNX</a>) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company&#39;s next phase of growth.</p><p xmlns="http://www.w3.org/1999/xhtml">Concurrent with Mr. Ciongoli&#39;s appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as an independent director since 2015, and Jean Bennett, M.D., Ph.D., who served as an independent director since 2021, are retiring from the Board.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;As REGENXBIO enters its next phase of growth, the Board has continued its strategic succession planning process to ensure the Company benefits from a complementary mix of scientific, clinical, commercial and capital markets expertise,&#34; said Curran Simpson, President and Chief Executive Officer of REGENXBIO. &#34;Greg brings a combination of financial and strategic expertise that will strengthen our Board as we advance our late-stage portfolio and continue our work to create life-changing treatments for patients and long-term value for our shareholders.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;We are grateful to Jerry and Jean for their exceptional service and meaningful contributions to REGENXBIO. Their leadership, insight, and commitment have helped shape the Company through a pivotal period of growth and innovation. As valued members of our Board, they have provided thoughtful guidance and steadfast support, leaving a lasting impact on REGENXBIO. We thank them for their many contributions and wish them every success in the future,&#34; said Ken Mills, Chairman of the Board.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;I am pleased to join REGENXBIO&#39;s Board during this exciting and transformational time for the Company,&#34; said Mr. Ciongoli. &#34;REGENXBIO has established a leadership position in gene therapy with a differentiated platform and compelling pipeline of potential first- and best-in-class medicines. I look forward to working with the Board and management team to help advance the Company&#39;s mission and strategic objectives.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">Mr. Ciongoli is the Founder and Managing Partner of Adiumentum Capital Management, an investment firm that works closely with organizations on capital structure optimization and asset allocation strategy. Prior to founding Adiumentum, Mr. Ciongoli spent over 16 years at The Baupost Group, where he served as Partner, Public Group Investing and led investments in public and private companies across multiple industries and geographies. Over the course of his career, he has focused extensively on healthcare investments, corporate governance, and strategic transformation across both public and private markets. Mr. Ciongoli currently serves as Board Chairman of Atara Biotherapeutics and is also a Board member at Zymeworks Inc. His prior board member and observer experience also includes Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Pharmaceuticals, Orexigen Therapeutics, Translate Bio, and others. Mr. Ciongoli received his MBA from Harvard Business School and BA from Princeton University&#39;s School of Public and International Affairs.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">ABOUT</b> <b xmlns="http://www.w3.org/1999/xhtml">REGENXBIO Inc.</b><br xmlns="http://www.w3.org/1999/xhtml"></br>REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121(clemidsogene lanparvovec) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO&#39;s AAV platform, including those receiving Novartis&#39; ZOLGENSMA<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup>. REGENXBIO&#39;s investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4758867-1&amp;h=1810176669&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4490696-1%26h%3D650859438%26u%3Dhttp%253A%252F%252Fwww.regenxbio.com%252F%26a%3Dwww.REGENXBIO.com&amp;a=www.REGENXBIO.com" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">www.REGENXBIO.com</b></a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">FORWARD-LOOKING STATEMENTS</b><br xmlns="http://www.w3.org/1999/xhtml"></br>This press release includes &#34;forward-looking statements,&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as &#34;believe,&#34; &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;anticipate,&#34; &#34;assume,&#34; &#34;design,&#34; &#34;intend,&#34; &#34;expect,&#34; &#34;could,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;seek,&#34; &#34;should,&#34; &#34;would&#34; or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO&#39;s future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO&#39;s expectations and predictions is subject to a number of risks and uncertainties, FDA&#39;s review process, the success of clinical trials conducted by REGENXBIO, the ability to obtain and maintain regulatory approval of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the &#34;Risk Factors&#34; and &#34;Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations&#34; sections of REGENXBIO&#39;s Annual Report on Form 10-K for the year ended December 31, 2025, and comparable &#34;risk factors&#34; sections of REGENXBIO&#39;s Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC&#39;s website at <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4758867-1&amp;h=143396860&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4490696-1%26h%3D2783391676%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3DWWW.SEC.GOV&amp;a=WWW.SEC.GOV" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">WWW.SEC.GOV</b></a>. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p><p xmlns="http://www.w3.org/1999/xhtml">Zolgensma<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">CONTACTS:</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Dana Cormack<br xmlns="http://www.w3.org/1999/xhtml"></br>Corporate Communications<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:Dcormack@regenxbio.com" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">Dcormack@regenxbio.com</b></a> </p><p xmlns="http://www.w3.org/1999/xhtml">George E. MacDougall<br xmlns="http://www.w3.org/1999/xhtml"></br>Investor Relations<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:IR@regenxbio.com" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">IR@regenxbio.com</b></a></p><div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder8688"><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1147952/RGNX-Logo.jpg?id=OA2908901" title="" alt=""></img></p></div><p xmlns="http://www.w3.org/1999/xhtml"> </p>
<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0">
</div>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=PH32945&amp;sd=2026-08-25"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/regenxbio-strengthens-board-of-directors-with-appointment-of-greg-ciongoli-302858908.html" target="_blank">https://www.prnewswire.com/news-releases/regenxbio-strengthens-board-of-directors-with-appointment-of-greg-ciongoli-302858908.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE REGENXBIO Inc.</p>

RGNX

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

REGENXBIO adds biotech veteran to board as late-stage catalysts loom

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>REGENXBIO appointed Greg Ciongoli to its Board of Directors, with two long-time directors retiring. The move supports a shift toward global commercialization of a late-stage gene-therapy portfolio. Ciongoli brings capital-structure and healthcare-investment expertise, aligning governance with upcoming catalysts around RGX-202, RGX-121, and ABBV-RGX-314 over the next 12–24 months.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Greg Ciongoli joins REGENXBIO board. Effective Aug 25, 2026, signaling governance refresh.</li><li>Jerry Karabelas and Jean Bennett retire from the board.</li><li>CEO: board refresh to support late-stage portfolio and global commercialization.</li><li>Late-stage pipeline includes RGX-202 and RGX-121, plus ABBV-RGX-314; catalysts ahead.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>REGENXBIO Inc. (RGNX)</strong>: Appointment of Greg Ciongoli to the board signals governance strengthening and strategic succession.</li><li><strong>Atara Biotherapeutics (ATRA)</strong>: Ciongoli is Board Chairman; could influence governance and strategic discussions affecting biotech peers.</li><li><strong>Zymeworks (ZYME)</strong>: Ciongoli previously on board; his broadened governance experience may affect cross-industry ties.</li><li><strong>Keryx Pharmaceuticals (KERX)</strong>: Past board involvement; signals breadth of governance network in biotech.</li><li><strong>Translate Bio (TBIO)</strong>: Past board observer/exposure; may highlight broader biotech governance insights.</li><li><strong>AbbVie (ABBV)</strong>: Collaboration on RGX-314 (lumparvovec) may provide near-term revenue/partner leverage.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The board appointment is a governance-focused event with potential implications for strategy, capital allocation, and execution as REGENXBIO advances its late-stage gene-therapy portfolio toward commercialization.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Board refresh could unlock further strategic and financial discipline.</li><li>Upcoming catalysts for RGX-202, RGX-121, and ABBV-RGX-314 may drive volatility.</li><li>AbbVie collaboration on RGX-314 provides potential upside exposure.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Greg Ciongoli appointed to REGENXBIO board, effective August 25, 2026.</li><li>Jerry Karabelas and Jean Bennett retire from the Board concurrent with appointment.</li><li>Ciongoli: Founder/Managing Partner of Adiumentum Capital; former Baupost Group leader.</li><li>Ciongoli also serves as Board Chairman of Atara Biotherapeutics; has other biotech board roles.</li><li>REGENXBIO late-stage pipeline: RGX-202 (Duchenne), RGX-121; ABBV-RGX-314 with AbbVie.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Cautiously bullish on RGNX over 6–12 months as governance strengthens and pipeline catalysts approach.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">ROCKVILLE, Md.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">Aug. 25, 2026</span> /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RGNX">RGNX</a>) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company&#39;s next phase of growth.</p><p xmlns="http://www.w3.org/1999/xhtml">Concurrent with Mr. Ciongoli&#39;s appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as an independent director since 2015, and Jean Bennett, M.D., Ph.D., who served as an independent director since 2021, are retiring from the Board.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;As REGENXBIO enters its next phase of growth, the Board has continued its strategic succession planning process to ensure the Company benefits from a complementary mix of scientific, clinical, commercial and capital markets expertise,&#34; said Curran Simpson, President and Chief Executive Officer of REGENXBIO. &#34;Greg brings a combination of financial and strategic expertise that will strengthen our Board as we advance our late-stage portfolio and continue our work to create life-changing treatments for patients and long-term value for our shareholders.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;We are grateful to Jerry and Jean for their exceptional service and meaningful contributions to REGENXBIO. Their leadership, insight, and commitment have helped shape the Company through a pivotal period of growth and innovation. As valued members of our Board, they have provided thoughtful guidance and steadfast support, leaving a lasting impact on REGENXBIO. We thank them for their many contributions and wish them every success in the future,&#34; said Ken Mills, Chairman of the Board.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;I am pleased to join REGENXBIO&#39;s Board during this exciting and transformational time for the Company,&#34; said Mr. Ciongoli. &#34;REGENXBIO has established a leadership position in gene therapy with a differentiated platform and compelling pipeline of potential first- and best-in-class medicines. I look forward to working with the Board and management team to help advance the Company&#39;s mission and strategic objectives.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">Mr. Ciongoli is the Founder and Managing Partner of Adiumentum Capital Management, an investment firm that works closely with organizations on capital structure optimization and asset allocation strategy. Prior to founding Adiumentum, Mr. Ciongoli spent over 16 years at The Baupost Group, where he served as Partner, Public Group Investing and led investments in public and private companies across multiple industries and geographies. Over the course of his career, he has focused extensively on healthcare investments, corporate governance, and strategic transformation across both public and private markets. Mr. Ciongoli currently serves as Board Chairman of Atara Biotherapeutics and is also a Board member at Zymeworks Inc. His prior board member and observer experience also includes Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Pharmaceuticals, Orexigen Therapeutics, Translate Bio, and others. Mr. Ciongoli received his MBA from Harvard Business School and BA from Princeton University&#39;s School of Public and International Affairs.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">ABOUT</b> <b xmlns="http://www.w3.org/1999/xhtml">REGENXBIO Inc.</b><br xmlns="http://www.w3.org/1999/xhtml"></br>REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121(clemidsogene lanparvovec) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO&#39;s AAV platform, including those receiving Novartis&#39; ZOLGENSMA<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup>. REGENXBIO&#39;s investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4758867-1&amp;h=1810176669&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4490696-1%26h%3D650859438%26u%3Dhttp%253A%252F%252Fwww.regenxbio.com%252F%26a%3Dwww.REGENXBIO.com&amp;a=www.REGENXBIO.com" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">www.REGENXBIO.com</b></a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">FORWARD-LOOKING STATEMENTS</b><br xmlns="http://www.w3.org/1999/xhtml"></br>This press release includes &#34;forward-looking statements,&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as &#34;believe,&#34; &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;anticipate,&#34; &#34;assume,&#34; &#34;design,&#34; &#34;intend,&#34; &#34;expect,&#34; &#34;could,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;seek,&#34; &#34;should,&#34; &#34;would&#34; or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO&#39;s future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO&#39;s expectations and predictions is subject to a number of risks and uncertainties, FDA&#39;s review process, the success of clinical trials conducted by REGENXBIO, the ability to obtain and maintain regulatory approval of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the &#34;Risk Factors&#34; and &#34;Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations&#34; sections of REGENXBIO&#39;s Annual Report on Form 10-K for the year ended December 31, 2025, and comparable &#34;risk factors&#34; sections of REGENXBIO&#39;s Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC&#39;s website at <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4758867-1&amp;h=143396860&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4490696-1%26h%3D2783391676%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3DWWW.SEC.GOV&amp;a=WWW.SEC.GOV" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">WWW.SEC.GOV</b></a>. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p><p xmlns="http://www.w3.org/1999/xhtml">Zolgensma<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">CONTACTS:</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Dana Cormack<br xmlns="http://www.w3.org/1999/xhtml"></br>Corporate Communications<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:Dcormack@regenxbio.com" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">Dcormack@regenxbio.com</b></a> </p><p xmlns="http://www.w3.org/1999/xhtml">George E. MacDougall<br xmlns="http://www.w3.org/1999/xhtml"></br>Investor Relations<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:IR@regenxbio.com" target="_blank" rel="nofollow"><b xmlns="http://www.w3.org/1999/xhtml">IR@regenxbio.com</b></a></p><div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder8688"><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1147952/RGNX-Logo.jpg?id=OA2908901" title="" alt=""></img></p></div><p xmlns="http://www.w3.org/1999/xhtml"> </p>
<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0">
</div>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=PH32945&amp;sd=2026-08-25"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/regenxbio-strengthens-board-of-directors-with-appointment-of-greg-ciongoli-302858908.html" target="_blank">https://www.prnewswire.com/news-releases/regenxbio-strengthens-board-of-directors-with-appointment-of-greg-ciongoli-302858908.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE REGENXBIO Inc.</p>

REGENXBIO appointed Greg Ciongoli to its Board of Directors, with two long-time directors retiring. The move supports a shift toward global commercialization of a late-stage gene-therapy portfolio. Ciongoli brings capital-structure and healthcare-investment expertise, aligning governance with upcoming catalysts around RGX-202, RGX-121, and ABBV-RGX-314 over the next 12–24 months.

News insight

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

AI summary

Sentiment rationale

Key facts

Corporate Developments